Key result
In anticoagulated patients with atrial fibrillation, hypertension was associated with a higher risk of ischaemic stroke or systemic embolism compared to no hypertension.
Why the study?
Hypertension is common in AF and increases complications like stroke and bleeding, prompting an assessment of history of hypertension, blood pressure control, and interaction with oral anticoagulant choice on outcomes.
Does hypertension increase the risk of stroke and bleeding in anticoagulated patients with atrial fibrillation, and does it modify the relative efficacy and safety of NOACs versus VKAs?
Meta-Analysis (n=71,527)
Does hypertension increase the risk of stroke and bleeding in anticoagulated patients with atrial fibrillation, and does it modify the relative efficacy and safety of NOACs versus VKAs?
Hypertension significantly increases the risk of stroke in anticoagulated patients with atrial fibrillation, but NOACs remain superior to VKAs regardless of blood pressure status.
Answers are grounded in this paper and cite their sources.
Hypertension elevates stroke risk despite anticoagulation in AF; reinforces consistent NOAC benefit over VKAs independent of blood pressure status.
BACKGROUND AND PURPOSE: Hypertension is common in patients with atrial fibrillation (AF) and carries an additional risk for complications, most notably stroke and bleeding. We assessed the history of hypertension, level of blood pressure control, and an interaction with the choice of oral anticoagulants on clinical outcomes. METHODS: We performed a systematic review and meta-analysis of studies that randomised patients to novel oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) and reported outcomes stratified by presence of hypertension. Collected outcomes were: ischaemic stroke or systemic embolism (SE), haemorrhagic stroke, intracranial haemorrhage and major bleeding. Log adjusted hazard ratios (HR) and corresponding standard error were calculated, and HRs were compared using Mantel-Haenszel random effects. Quality of the evidence was assessed with Cochrane risk of bias tool. RESULTS: Five high-quality studies were eligible, including 71.527 participants who received NOACs (apixaban, dabigatran, edoxaban, rivaroxaban) or VKAs, with median follow-up of 1.8-2.8 years. Compared with patients without hypertension, those with hypertension had higher adjusted risk for ischaemic stroke/SE (HR: 1.25, 95%-CI:1.09, 1.43) and haemorrhagic stroke (HR:1.98, 1.24-3.16). On a continuous scale, the risk of ischaemic stroke/SE increased 6-7% per 10 mmHg increase in systolic blood pressure. No interactions were found between the efficacy or safety of NOACs versus VKAs in the presence or absence of hypertension. In both groups, the use of NOACs led to a lower risk of ischaemic stroke/SE, haemorrhagic stroke and intracranial haemorrhage compared with patients that used VKAs. CONCLUSIONS: Adequate blood pressure management is vital to optimally reduce the risk of stroke in patients with atrial fibrillation. The benefits of NOACs over VKAs, also apply to patients with elevated blood pressure.
No takes yet. Share an insight, caveat, or question.
Harskamp et al. (2021) conducted a meta-analysis in Atrial fibrillation (n=71,527). Hypertension vs. No hypertension was evaluated on Ischaemic stroke or systemic embolism (SE) (HR 1.25, 95% CI 1.09-1.43). In anticoagulated patients with atrial fibrillation, hypertension was associated with a higher risk of ischaemic stroke or systemic embolism compared to no hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: